How can heart failure advocates in Spain seize current opportunities to improve care?

News & Events

22 September 2022


This year, Spain has become one of the few countries in Europe with a national strategy on cardiovascular health that prioritises heart failure among other conditions. But how heart failure can advocates fully seize this and other key opportunities to ensure national recommendations and targets for heart failure care are implemented at the local level?

Our latest policy brief attempts to answer this question, examining existing opportunities and mechanisms to advocate for guideline-recommended care in Spain.  This includes securing regional funding from organisations driving digital transformation, or calling on regional technology assessment agencies collecting heart failure data to provide policy recommendations.

This briefing is the first in our new series, From guidelines to action: opportunities for heart failure advocacy, which aims to equip advocates with a targeted analysis of the opportunities available in their countries and specific actions to take forward. These actions were developed based on successful examples from a number of health advocacy areas and interviews with national heart failure experts. Upcoming reports will focus on France, Germany and Italy.

Download the report


More from News & Events

It is time to put quality of life at the centre of heart fai
It is time to put quality of life at the centre of heart fai...
15 November 2022
More than 90% of people with heart failure would like regular discussion about quality of life to be part of their care, but this only happens for 20%. ...
Read article
The Heart Failure Policy Summit will put people with heart f
The Heart Failure Policy Summit will put people with heart f...
27 September 2022
The Heart Failure Policy Summit will offer an opportunity for heart failure advocates to build alliances across disease areas and link to broader health policy agendas....
Read article
The Heart Failure Policy Network is made possible with financial support from AstraZeneca, CSL Vifor, Boehringer Ingelheim, Roche Diagnostics and Bayer AG. The content produced by the Network is non-promotional and not biased to any specific treatment or therapy. All outputs are guided and endorsed by the Network’s members.